BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
Locatelli SL
Leukemia. 2014 Feb 24;28(9):1861-71. doi: 10.1038/leu.2014.81
Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.
Castagna L
Biol Blood Marrow Transplant. 2014 Feb 13;20(5):724-9. doi: 10.1016/j.bbmt.2014.02.001
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Magni M
Bone Marrow Transplant. 2014 Jan 20;49(4):485-91. doi: 10.1038/bmt.2013.214
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.
Necchi A
Clin Genitourin Cancer. 2013 Nov 13;12(3):196-202.e1. doi: 10.1016/j.clgc.2013.11.021
Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
Farina L
Bone Marrow Transplant. 2013 Dec 9;49(3):453-5. doi: 10.1038/bmt.2013.193
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies.
Marconi M
Cell Death Dis. 2013 Oct 17;4(10):e863. doi: 10.1038/cddis.2013.389
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Devizzi L
J Clin Oncol. 2013 Jul 15;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L
Leuk Lymphoma. 2013 Jun 14;55(2):331-6. doi: 10.3109/10428194.2013.802783
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Carlo-Stella C
PLoS One. 2013 Apr 19;8(4):e61603. doi: 10.1371/journal.pone.0061603
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Giacomini A
Angiogenesis. 2013 Apr 20;16(3):707-22. doi: 10.1007/s10456-013-9348-7